Immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors that restore T cell anti-tumor activity by blocking the PD1/PD-L1 pathway are more used and effective immunotherapy therapies (5). Here, PDCD1 is linked to neoplasm.